Adamis pharmaceuticals provides enrollment update of subjects in phase 2/3 study of tempol for the treatment of covid-19

San diego, feb. 07, 2022 (globe newswire) -- adamis pharmaceuticals corporation (nasdaq: admp) today announced the enrollment and dosing of more than 100 subjects in the company's ongoing phase 2/3 study of tempol for the treatment of covid-19. the data safety monitoring board (dsmb) will now examine clinical and safety data from the first 50 subjects as part of the first interim analysis.
ADMP Ratings Summary
ADMP Quant Ranking